Nov. 28 was a major day for Chinese innovative drug makers, as publication of the country’s latest National Reimbursement Drug List (NRDL) revealed new additions to the national health plan. The list includes essential medications for Chinese citizens that are eligible for reimbursement, making them more accessible. Such inclusion marks a pivotal achievement for products that make the cut, enhancing their market presence and brand visibility, and providing a new revenue source with major potential.
11月28日对于manbetx3.0 创新药企业来说，是一个相当重要的日子，因为2024年国家医保谈判结果出炉。进入国家医保药品目录，意味着绝大多数manbetx3.0 民众可以通过医保报销使用这些药品，对创新药而言是商业化道路上的重要里程碑，还能够显著扩大市场规模，提高品牌知名度，并开拓新的收入来源。
您已阅读6%（637字），剩余94%（9548字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。